Verrica Pharmaceuticals Inc
VRCA6.910USD
+0.300+4.54%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
65.58M시가총액
손실P/E TTM
자세한 내용은 Verrica Pharmaceuticals Inc 회사
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Verrica Pharmaceuticals Inc 정보
종목 코드 VRCA
회사 이름Verrica Pharmaceuticals Inc
상장일Jun 15, 2018
CEORieger (Jayson)
직원 수71
유형Ordinary Share
회계 연도 종료Jun 15
주소44 West Gay Street
도시WEST CHESTER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호19380
전화14844533300
웹사이트https://verrica.com/
종목 코드 VRCA
상장일Jun 15, 2018
CEORieger (Jayson)
Verrica Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.30K
+94311.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+10000.00%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
+2357.00%
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.30K
+94311.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+10000.00%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
+2357.00%
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
Manning (Paul B.)
28.51%
BKB Growth Investments LLC
20.94%
Caligan Partners, LP
5.78%
Affinity Asset Advisors LLC
4.42%
Armistice Capital LLC
4.00%
기타
36.35%
주주
주주
비율
Manning (Paul B.)
28.51%
BKB Growth Investments LLC
20.94%
Caligan Partners, LP
5.78%
Affinity Asset Advisors LLC
4.42%
Armistice Capital LLC
4.00%
기타
36.35%
주주 유형
주주
비율
Individual Investor
31.47%
Corporation
21.10%
Hedge Fund
14.84%
Investment Advisor/Hedge Fund
2.43%
Investment Advisor
1.54%
Venture Capital
0.18%
Family Office
0.11%
Research Firm
0.02%
기타
28.32%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
174
3.04M
19.01%
-494.27K
2025Q3
171
2.46M
26.06%
-1.46M
2025Q2
183
8.91M
96.35%
+3.15M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Manning (Paul B.)
4.56M
28.51%
+1.42M
+45.27%
Nov 25, 2025
BKB Growth Investments LLC
3.35M
20.94%
+2.75M
+460.29%
Nov 25, 2025
Caligan Partners, LP
923.91K
5.78%
--
--
Dec 26, 2025
Affinity Asset Advisors LLC
707.34K
4.42%
+707.34K
--
Nov 25, 2025
Armistice Capital LLC
639.19K
4%
-248.94K
-28.03%
Sep 30, 2025
Boothbay Fund Management, LLC
280.73K
1.76%
+280.73K
--
Sep 30, 2025
Stalfort (John A)
187.38K
1.17%
+23.81K
+14.56%
Apr 01, 2025
Rieger (Jayson)
183.30K
1.15%
+94.31K
+105.98%
Nov 25, 2025
The Vanguard Group, Inc.
225.21K
1.41%
+8.38K
+3.86%
Sep 30, 2025
Millennium Management LLC
71.99K
0.45%
-18.72K
-20.64%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
더 보기
iShares Micro-Cap ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0%
Dimensional US Core Equity 1 ETF
비율0%
Global X Russell 2000 Covered Call ETF
비율0%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Global X Russell 2000 ETF
비율0%
iShares Russell 2000 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jul 23, 2025
Merger
10→1
날짜
배당락일
유형
비율
Jul 23, 2025
Merger
10→1
